Melittin-A Natural Peptide from Bee Venom Which Induces Apoptosis in Human Leukaemia Cells. 2020

Michal Ceremuga, and Maksymilian Stela, and Edyta Janik, and Leslaw Gorniak, and Ewelina Synowiec, and Tomasz Sliwinski, and Przemyslaw Sitarek, and Joanna Saluk-Bijak, and Michal Bijak
Military Institute of Armament Technology, Prymasa Stefana WyszyƄskiego 7, 05-220 Zielonka, Poland.

Bee venom is a very complex mixture produced and secreted by the honeybee (Apis mellifera). Melittin is a major component of bee venom that accounts for about 52% of its dry mass. A vast number of studies have been dedicated to the effects of melittin's regulation of apoptosis and to the factors that induce apoptosis in various types of cancer such as breast, ovarian, prostate, lung. The latest evidence indicates its potential as a therapeutic agent in the treatment of leukaemia. The aim of our present study is to evaluate melittin's ability to induce apoptosis in leukaemia cell lines of different origin acute lymphoblastic leukaemia (CCRF-CEM) and chronic myelogenous leukaemia (K-562). We demonstrated that melittin strongly reduced cell viability in both leukaemia cell lines but not in physiological peripheral blood mononuclear cells (PMBCs). Subsequent estimated parameters (mitochondrial membrane potential, Annexin V binding and Caspases 3/7 activity) clearly demonstrated that melittin induced apoptosis in leukaemia cells. This is a very important step for research into the development of new potential anti-leukaemia as well as anticancer therapies. Further analyses on the molecular level have been also planned (analysis of proapoptotic genes expression and DNA damages) for our next research project, which will also focus on melittin.

UI MeSH Term Description Entries
D007963 Leukocytes, Mononuclear Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules. Mononuclear Leukocyte,Mononuclear Leukocytes,PBMC Peripheral Blood Mononuclear Cells,Peripheral Blood Human Mononuclear Cells,Peripheral Blood Mononuclear Cell,Peripheral Blood Mononuclear Cells,Leukocyte, Mononuclear
D008555 Melitten Basic polypeptide from the venom of the honey bee (Apis mellifera). It contains 26 amino acids, has cytolytic properties, causes contracture of muscle, releases histamine, and disrupts surface tension, probably due to lysis of cell and mitochondrial membranes. Melittin,Mellitin
D008928 Mitochondria Semiautonomous, self-reproducing organelles that occur in the cytoplasm of all cells of most, but not all, eukaryotes. Each mitochondrion is surrounded by a double limiting membrane. The inner membrane is highly invaginated, and its projections are called cristae. Mitochondria are the sites of the reactions of oxidative phosphorylation, which result in the formation of ATP. They contain distinctive RIBOSOMES, transfer RNAs (RNA, TRANSFER); AMINO ACYL T RNA SYNTHETASES; and elongation and termination factors. Mitochondria depend upon genes within the nucleus of the cells in which they reside for many essential messenger RNAs (RNA, MESSENGER). Mitochondria are believed to have arisen from aerobic bacteria that established a symbiotic relationship with primitive protoeukaryotes. (King & Stansfield, A Dictionary of Genetics, 4th ed) Mitochondrial Contraction,Mitochondrion,Contraction, Mitochondrial,Contractions, Mitochondrial,Mitochondrial Contractions
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004249 DNA Damage Injuries to DNA that introduce deviations from its normal, intact structure and which may, if left unrepaired, result in a MUTATION or a block of DNA REPLICATION. These deviations may be caused by physical or chemical agents and occur by natural or unnatural, introduced circumstances. They include the introduction of illegitimate bases during replication or by deamination or other modification of bases; the loss of a base from the DNA backbone leaving an abasic site; single-strand breaks; double strand breaks; and intrastrand (PYRIMIDINE DIMERS) or interstrand crosslinking. Damage can often be repaired (DNA REPAIR). If the damage is extensive, it can induce APOPTOSIS. DNA Injury,DNA Lesion,DNA Lesions,Genotoxic Stress,Stress, Genotoxic,Injury, DNA,DNA Injuries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001514 Bee Venoms Toxins obtained from Apis mellifera (honey bee) and related species. They contain various enzymes, polypeptide toxins, and other substances, some of which are allergenic or immunogenic or both. These venoms were formerly used in rheumatism to stimulate the pituitary-adrenal system. Apis Venoms,Honeybee Venom,Honeybee Venoms,Apitoxin,Bee Venom,Venom, Bee,Venom, Honeybee,Venoms, Apis,Venoms, Bee,Venoms, Honeybee

Related Publications

Michal Ceremuga, and Maksymilian Stela, and Edyta Janik, and Leslaw Gorniak, and Ewelina Synowiec, and Tomasz Sliwinski, and Przemyslaw Sitarek, and Joanna Saluk-Bijak, and Michal Bijak
June 1971, European journal of biochemistry,
Michal Ceremuga, and Maksymilian Stela, and Edyta Janik, and Leslaw Gorniak, and Ewelina Synowiec, and Tomasz Sliwinski, and Przemyslaw Sitarek, and Joanna Saluk-Bijak, and Michal Bijak
March 1968, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
Michal Ceremuga, and Maksymilian Stela, and Edyta Janik, and Leslaw Gorniak, and Ewelina Synowiec, and Tomasz Sliwinski, and Przemyslaw Sitarek, and Joanna Saluk-Bijak, and Michal Bijak
March 1973, European journal of biochemistry,
Michal Ceremuga, and Maksymilian Stela, and Edyta Janik, and Leslaw Gorniak, and Ewelina Synowiec, and Tomasz Sliwinski, and Przemyslaw Sitarek, and Joanna Saluk-Bijak, and Michal Bijak
January 1995, Ukrainskii biokhimicheskii zhurnal (1978),
Michal Ceremuga, and Maksymilian Stela, and Edyta Janik, and Leslaw Gorniak, and Ewelina Synowiec, and Tomasz Sliwinski, and Przemyslaw Sitarek, and Joanna Saluk-Bijak, and Michal Bijak
August 2017, Cancer letters,
Michal Ceremuga, and Maksymilian Stela, and Edyta Janik, and Leslaw Gorniak, and Ewelina Synowiec, and Tomasz Sliwinski, and Przemyslaw Sitarek, and Joanna Saluk-Bijak, and Michal Bijak
January 1983, Biopolymers,
Michal Ceremuga, and Maksymilian Stela, and Edyta Janik, and Leslaw Gorniak, and Ewelina Synowiec, and Tomasz Sliwinski, and Przemyslaw Sitarek, and Joanna Saluk-Bijak, and Michal Bijak
March 2015, Chemistry (Weinheim an der Bergstrasse, Germany),
Michal Ceremuga, and Maksymilian Stela, and Edyta Janik, and Leslaw Gorniak, and Ewelina Synowiec, and Tomasz Sliwinski, and Przemyslaw Sitarek, and Joanna Saluk-Bijak, and Michal Bijak
September 1979, Clinical allergy,
Michal Ceremuga, and Maksymilian Stela, and Edyta Janik, and Leslaw Gorniak, and Ewelina Synowiec, and Tomasz Sliwinski, and Przemyslaw Sitarek, and Joanna Saluk-Bijak, and Michal Bijak
June 1986, Inflammation,
Michal Ceremuga, and Maksymilian Stela, and Edyta Janik, and Leslaw Gorniak, and Ewelina Synowiec, and Tomasz Sliwinski, and Przemyslaw Sitarek, and Joanna Saluk-Bijak, and Michal Bijak
January 2012, International journal of urology : official journal of the Japanese Urological Association,
Copied contents to your clipboard!